GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (STU:C6K0) » Definitions » Cyclically Adjusted PB Ratio

Avalo Therapeutics (STU:C6K0) Cyclically Adjusted PB Ratio : (As of Jun. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Avalo Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avalo Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Avalo Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Cyclically Adjusted PB Ratio Chart

Avalo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avalo Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avalo Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Avalo Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Cyclically Adjusted PB Ratio falls into.



Avalo Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Avalo Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Avalo Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-100.121/131.7762*131.7762
=-100.121

Current CPI (Mar. 2024) = 131.7762.

Avalo Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -10,677.000 99.070 -14,201.865
201503 -13,637.500 99.621 -18,039.330
201506 -690.333 100.684 -903.515
201509 -9,756.667 100.392 -12,806.826
201512 4,003.667 99.792 5,286.856
201603 2,658.333 100.470 3,486.649
201606 1,652.667 101.688 2,141.668
201609 166.032 101.861 214.793
201612 59.756 101.863 77.304
201703 -105.291 102.862 -134.888
201706 569.388 103.349 726.003
201709 2,050.718 104.136 2,595.038
201712 2,167.772 104.011 2,746.445
201803 1,827.406 105.290 2,287.110
201806 1,402.472 106.317 1,738.318
201809 1,183.994 106.507 1,464.905
201812 6.400 105.998 7.956
201903 7.124 107.251 8.753
201906 5.452 108.070 6.648
201909 5.759 108.329 7.005
201912 6.577 108.420 7.994
202003 18.122 108.902 21.929
202006 35.001 108.767 42.405
202009 25.517 109.815 30.620
202012 15.733 109.897 18.865
202103 21.621 111.754 25.495
202106 537.433 114.631 617.814
202109 878.538 115.734 1,000.312
202112 521.655 117.630 584.392
202203 147.063 121.301 159.763
202206 -143.659 125.017 -151.426
202209 -52.205 125.227 -54.935
202212 -262.255 125.222 -275.982
202303 -106.418 127.348 -110.119
202306 -109.968 128.729 -112.571
202309 17.177 129.860 17.431
202312 8.354 129.419 8.506
202403 -100.121 131.776 -100.121

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Avalo Therapeutics  (STU:C6K0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Avalo Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalo Therapeutics (STU:C6K0) Business Description

Traded in Other Exchanges
Address
540 Gaither Road, Suite 400, Rockville, MD, USA, 20850
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.

Avalo Therapeutics (STU:C6K0) Headlines

No Headlines